Insights Into Breast Cancer
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer. Insights on current treatment practice attitudes toward recently introduced and upcoming agents
Meeting Moderator
Sushil Bhardwaj, MD
Good Samaritan Hospital Suffern, NY, USA
Look Inside This Report
Download a sample of this report and start discovering the insights
Report Snapshot
Insights on the following breast cancer therapies were obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A roundtable discussion, moderated by an Axess Oncology Network Physician, focusing on treatment of metastatic breast cancer was held on August 24, 2019, in Washington, DC, US
- Disease state and data presentations were developed in conjunction with a medical expert from the University of Pittsburgh
- The group of advisors comprised 14 community oncologists from the Northeast, US
- Data collection was accomplished through use of audience response system questioning and moderated discussion
